Trials / Conditions / Progesterone Receptor-negative Breast Cancer

Progesterone Receptor-negative Breast Cancer

19 registered clinical trials studyying Progesterone Receptor-negative Breast Cancer.

Status	Trial	Sponsor	Phase
Terminated	A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) NCT04504916	VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Phase 2
Active Not Recruiting	Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating P NCT02315196	Rutgers, The State University of New Jersey	Phase 2
Completed	MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer NCT01805076	Alliance for Clinical Trials in Oncology	Phase 3
Completed	Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabin NCT01881230	Celgene	Phase 2 / Phase 3
Completed	Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Br NCT01818063	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Phase 2
Unknown	Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients NCT01372579	Northwestern University	Phase 2
Terminated	Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery NCT01234532	University of Maryland, Baltimore	Phase 2
Completed	Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast NCT01104259	University of Washington	Phase 1
Terminated	Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, o NCT01151449	National Cancer Institute (NCI)	Phase 2
Withdrawn	Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer NCT01100489	Case Comprehensive Cancer Center	Phase 2
Completed	Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer NCT01037790	Abramson Cancer Center at Penn Medicine	Phase 2
Completed	F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormon NCT00602043	National Cancer Institute (NCI)	Phase 2
Completed	Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer NCT00733408	University of Washington	Phase 2
Completed	Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By S NCT00559507	National Cancer Institute (NCI)	Phase 2
Completed	Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer NCT00516243	National Cancer Institute (NCI)	Phase 1
Completed	Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Brea NCT00577122	Indiana University	Phase 2
Completed	Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer T NCT00194779	University of Washington	Phase 2
Completed	7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681	National Cancer Institute (NCI)	Phase 1
Completed	Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in NCT00003199	Fred Hutchinson Cancer Center	Phase 2